If your child has been diagnosed with a peanut allergy, this is one of the first questions every parent asks: will they outgrow it? It's the question that lets families imagine a future without daily worry about labels, birthday parties, and accidental exposure. It's also the question with the most outdated, confusing, and sometimes contradictory information online.

So here's the honest answer, based on the most recent published research, with the sources cited so you can verify any of this for yourself. We'll also walk through what this data actually means for your family — including the part of the conversation that has changed most dramatically in the last few years: you don't have to just wait and hope anymore.

The Headline Number: Roughly 20%

The most widely cited statistic in peanut allergy research is that approximately 20% of children with peanut allergy outgrow it. This figure comes from a landmark 2001 study published in the Journal of Allergy and Clinical Immunology and has been the consensus number in the field for over two decades. Food Allergy Research & Education (FARE), the largest food allergy nonprofit in the U.S., still uses this figure in their patient-facing education materials.

So if you're looking for the simple answer to "will my child outgrow this?" — the simple answer is: probably not. Roughly four out of every five children with peanut allergy will continue to have it into adulthood.

But "roughly 20%" is the floor of what newer research is showing. The picture is actually more interesting and more nuanced than the headline number suggests.

The 2024 Update: A More Detailed Picture

In 2024, researchers at Murdoch Children's Research Institute published a study in the journal Allergy that followed children with peanut allergy from infancy through age 10. Their findings:

• Approximately one-third of children resolved their peanut allergy by age 10 — somewhat higher than the classic 20% number.
• Of the children who did outgrow it, the great majority did so by age 6.
• After age 6, the chance of natural resolution drops sharply. Children still allergic at 6 are very likely to be allergic at 10.
• Two specific antibodies in the blood (sIgG4 and sIgE) change in characteristic ways in children who are going to outgrow it — opening the possibility of better predicting which children will resolve naturally.

Meanwhile, more conservative recent estimates from clinicians have pointed to a figure closer to 10% in some populations. The variation depends on the specific population studied, the diagnostic criteria, and the time period of follow-up. The takeaway across all of this research is consistent: peanut allergy outgrowth is uncommon, it happens early when it happens at all, and the longer a child remains allergic, the less likely natural resolution becomes.

Why Peanut Specifically Is So Persistent

Many parents come into this thinking peanut allergy will follow the same pattern as milk or egg allergy — and it doesn't.

For milk allergy, roughly 80% to 90% of children outgrow it, often by school age. The same is true for egg allergy. The broader picture on outgrowing food allergies is much more optimistic when the allergen is milk or egg. But peanut, tree nut, sesame, and shellfish are categorically different. These allergies tend to be persistent. Peanut allergy is among the most persistent of all common food allergies — likely due to differences in how the immune system recognizes and stores memory of peanut proteins compared to milk or egg proteins.

This is part of why peanut allergy is the leading cause of food-related anaphylaxis and the most-researched food allergy in the world. It's the persistence — and the severity — that drives clinical urgency.

What "Outgrowing" Actually Looks Like

A practical note worth making: when researchers say a child "outgrew" a peanut allergy, they typically mean the child successfully passed an oral food challenge — eating measured amounts of peanut under medical supervision without a reaction. Blood test changes alone (lower IgE levels) suggest a child might be a candidate for retesting, but they're not the same as confirmed resolution.

If your child has a peanut allergy and your allergist mentions that the blood test numbers have come down or are trending favorably, that's worth following up on. A controlled oral food challenge is how outgrowth is actually confirmed. Don't have a "trial run" at home — accidental peanut exposure at home is a different scenario than supervised challenge in a clinic, and the difference is medically significant.

The Conversation That's Changed: You Don't Have to Wait Anymore

For most of medical history, the only conversation a family could have about a persistent peanut allergy was about managing avoidance, carrying epinephrine, and hoping for one of those 1-in-5 outcomes. That's no longer the only conversation.

Three FDA-approved treatment options now exist, all available at our Burbank clinic and at a small number of other dedicated food allergy specialty centers:

Palforzia — FDA-approved oral immunotherapy specifically for peanut allergy

Originally approved for ages 4 to 17 and now approved for ages 1 to 3 (as of July 2024). Through a structured protocol of gradually increasing peanut protein doses, Palforzia trains the immune system to tolerate up to one peanut's worth of protein per day. That doesn't mean a child can eat peanut butter freely — it means the threshold for accidental exposure causing a serious reaction is dramatically raised. Clinical trial data shows the great majority of participants achieve the maintenance dose, with a substantial protective effect on what happens during accidental exposure.

Xolair (omalizumab) — FDA-approved injection that reduces reactions from accidental exposure

Approved in February 2024 for food allergy in adults and children one year and older. Xolair binds to IgE antibodies in the bloodstream before they can trigger an allergic reaction. In the trial that led to approval, 68% of patients on Xolair could consume roughly six times more peanut without a moderate or severe reaction than they could before treatment — compared to 5% of placebo patients reaching the same threshold. Xolair also covers multiple allergens at the same time, which matters for children with peanut plus other food allergies.

Traditional oral immunotherapy (OIT) — Decades of evidence, multiple allergens

For peanut and many other allergens, traditional OIT uses compounded food protein under a personalized protocol. Published clinical research shows 60% to 85% of patients achieve meaningful desensitization, depending on the allergen, the protocol, and the population. Traditional OIT is the most flexible option — it can be customized in ways the FDA-approved products can't.

For a side-by-side breakdown of how the three approaches differ in mechanism, age eligibility, time commitment, cost, and what kind of outcome they produce, see our full comparison guide on Xolair, OIT, and Palforzia.

The Reframe: From "Hope" to "Plan"

Here's the conversation we have with families at our Burbank clinic. The old framing of peanut allergy went something like this: avoid peanuts, carry epinephrine, hope your child is one of the lucky 20%.

The new framing is different. It still involves avoidance and emergency preparedness — those don't change. But it adds two more components: a candidacy evaluation for treatment, and a plan. The plan doesn't have to mean starting treatment tomorrow. It might mean monitoring antibody levels and waiting until age 6 or 7 to see if natural resolution is going to happen. It might mean starting Palforzia early in the toddler-window when the data on early intervention is most favorable. It might mean Xolair for a family with multiple food allergies. It might mean traditional OIT for an older child whose family wants the option to incorporate peanut into normal eating. It might mean watchful waiting with a clear plan for when to reassess.

What's no longer true is that "hope" is the only option. There is now a real menu of choices, with real published efficacy data behind each one, and decisions that can be customized to your specific child, allergen profile, age, and family goals.

When to Get an Evaluation

Some practical guidance on timing:

• Diagnosed but you haven't seen a specialist recently? Worth scheduling a re-evaluation. The treatment landscape has changed significantly since 2024 — what was true even two years ago may not reflect what's now available for your child.
• Child between 1 and 3 years old? The toddler window for Palforzia is real and the immunological case for earlier intervention is well-supported. An evaluation now is meaningfully different from an evaluation in two years.
• Child has been allergic since infancy and is now 6 or older? Natural resolution becomes statistically less likely beyond this point. A treatment evaluation becomes more relevant rather than less.
• Recent blood test numbers trending down? Talk to your allergist about whether an oral food challenge is appropriate. Confirmed resolution changes everything.
• Child has multiple food allergies? The Xolair conversation is particularly relevant — handling several allergens with a single approach is one of its biggest practical advantages. Our Xolair guide covers this in detail.

What an Evaluation Looks Like

A peanut allergy evaluation at our Burbank clinic is straightforward. It typically includes:

• A review of your child's medical history and any prior diagnostic testing.
• Updated skin prick testing or blood testing (typically covered by insurance as standard diagnostics).
• Where appropriate, an oral food challenge to confirm or rule out current allergy status.
• A conversation about treatment options — Palforzia, Xolair, OIT, combination approaches, or watchful waiting — and what fits your specific child and family.
• A clear plan with next steps.

For a fuller picture of what the first treatment day actually looks like if you choose to move forward, see our hour-by-hour walkthrough of the first OIT day.

The Bottom Line for LA Families

If your child has a peanut allergy and you've been quietly hoping they'll outgrow it, here's the honest summary: the odds of natural resolution are roughly 1 in 5, the window for natural resolution typically closes by age 6 or so, and meanwhile, the treatment options available to your family in 2026 are far more substantial than they've ever been. You don't have to choose between "wait and hope" and "give up." There's a third option that didn't exist five years ago: have an informed conversation about whether and how to actively reduce your child's risk.

If you're in Burbank, Glendale, Pasadena, Sherman Oaks, Studio City, North Hollywood, La Crescenta, or anywhere across the greater Los Angeles area, the most useful first step is an evaluation. There's no commitment to start treatment from the evaluation — many families leave with a "let's monitor and revisit in a year" plan, and that's a perfectly valid outcome. What changes is that you walk out with information instead of uncertainty.

Schedule a peanut allergy evaluation at the LAFAI Burbank clinic →

This article cites publicly available research on peanut allergy outgrowth, including the 2001 Skolnick et al. study published in the Journal of Allergy and Clinical Immunology, the 2024 Murdoch Children's Research Institute study published in Allergy, FARE published statistics, and FDA approval information for Palforzia and Xolair. Specific outgrowth percentages vary by study population, diagnostic criteria, and length of follow-up. This guide is educational and does not constitute medical advice. Treatment decisions should be made in consultation with a board-certified Allergy and Immunology specialist who has personally evaluated the patient.

‍